Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
UB-311 extension in mild Alzheimer's disease
NCT03531710Phase 2Terminated
- Sponsor
- Vaxxinity
- Start
- Aug 2018
- Primary completion
- Oct 2019
- Modality
- Antisense DNA, Vaccines & Immunotherapeutics, Small Interfering RNA (siRNA)
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of UB-311 in Alzheimer's disease (AD) (2 arms), sponsored by Vaxxinity. Primary endpoints: Incidence of Adverse Event (AE)/Serious Adverse Event (SAE) at 326 days and Change From Baseline and Through to the End of the Study in Anti-Aβ Antibody Titers at 326 days. Started Aug 2018; status: terminated.
02
Drugs
UB-311
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NCT03531710.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03531710.